BIONDVAX PHARMA/S (NASDAQ:BVXV) Expected to Post Earnings of -$0.02 Per Share

Brokerages expect BIONDVAX PHARMA/S (NASDAQ:BVXV) to report ($0.02) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have provided estimates for BIONDVAX PHARMA/S’s earnings. BIONDVAX PHARMA/S posted earnings of ($1.12) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 98.2%. The business is expected to issue its next earnings report on Wednesday, August 28th.

According to Zacks, analysts expect that BIONDVAX PHARMA/S will report full-year earnings of ($0.08) per share for the current fiscal year. For the next fiscal year, analysts expect that the firm will post earnings of ($0.07) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow BIONDVAX PHARMA/S.

BIONDVAX PHARMA/S (NASDAQ:BVXV) last released its quarterly earnings results on Thursday, May 30th. The company reported $0.02 earnings per share (EPS) for the quarter.

Separately, ValuEngine upgraded shares of BIONDVAX PHARMA/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 26th.

Shares of NASDAQ BVXV traded down $0.37 during mid-day trading on Monday, hitting $6.01. The company had a trading volume of 2,894 shares, compared to its average volume of 3,874. The firm’s 50-day moving average price is $6.05. BIONDVAX PHARMA/S has a 12 month low of $3.51 and a 12 month high of $7.26. The company has a market cap of $40.55 million, a price-to-earnings ratio of -1.67 and a beta of 1.12.

BIONDVAX PHARMA/S Company Profile

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.

See Also: What is a Tariff?

Get a free copy of the Zacks research report on BIONDVAX PHARMA/S (BVXV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.